Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

MHRA-aligned GLP Bioanalysis of Vector Shedding for AAV Gene Therapies using qPCR and ELISA

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

MHRA-aligned GLP Bioanalysis of Vector Shedding for AAV Gene Therapies using qPCR and ELISA

AAV Vector Shedding Bioanalysis: GxP qPCR & ELISA Assays for MHRA Submissions

CELL & GENE | RNA | BIOLOGICS

What biological matrices are typically analyzed for AAV vector shedding studies?
For a comprehensive assessment aligned with regulatory expectations, we routinely process and analyze a wide range of matrices including whole blood, plasma, serum, saliva, urine, feces, and various tissue swabs (e.g., nasal, rectal, dermal). Matrix selection is determined by the AAV serotype, route of administration, and specific program goals.
What is the typical Lower Limit of Quantification (LLOQ) for a qPCR-based shedding assay?
Our validated qPCR assays are optimized to achieve high sensitivity, with the LLOQ established and documented for each specific vector and matrix combination. This ensures the limit of quantification meets the stringent requirements for regulatory assessment. Sensitivity is highly dependent on the vector construct, primer/probe design, and sample matrix, and is a core component of our GxP validation process.
How do you ensure assay specificity against endogenous host DNA sequences?
Assay specificity is a core validation parameter. Our bioinformatic design process targets unique sequences within the vector construct, such as the ITRs, promoter, or transgene cassette, that have no homology with the host genome. Specificity is then empirically confirmed during validation by testing the assay against a panel of naive, non-dosed biological matrices.
Are these bioanalytical methods fully validated to GxP standards for MHRA submission?
Yes. All pivotal bioanalytical assays are developed and validated in our GxP-compliant laboratories according to current regulatory guidelines. The validation package for each assay includes a comprehensive assessment of specificity, sensitivity, linearity, precision, accuracy, and stability, generating a dataset suitable for inclusion in Clinical Trial Application (CTA) filings with the MHRA and other global agencies.

To support Clinical Trial Applications (CTAs) for AAV-based gene therapies, regulatory bodies including the UK’s MHRA require robust data on vector shedding. This assessment quantifies the presence of vector DNA in various biological fluids and excreta over time, informing patient safety and environmental risk profiles. Franklin Biolabs provides fully validated, GxP-compliant qPCR and ELISA assays to precisely measure vector shedding and biodistribution, delivering submission-ready data packages that support accelerated development timelines.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Quantitative Bioanalysis for AAV Biodistribution

Characterizing the biodistribution and shedding profile of an AAV vector is a fundamental component of any preclinical safety program. We employ quantitative polymerase chain reaction (qPCR) as the principal method for detecting and quantifying vector DNA in diverse biological matrices. This technique provides the high sensitivity and specificity required to track vector clearance and persistence.

Complementary immunoassays can provide additional context:

  • Neutralizing Antibody (NAb) Assays: ELISA-based methods to quantify the host immune response to the AAV capsid.

  • Capsid Protein Quantification: Assays to measure the presence of AAV capsid proteins, offering a different perspective on vector distribution.

The selection of bioanalytical methods is tailored to the specific questions of the development program.

Assay Type Primary Analyte Key Application in Shedding Studies Regulatory Standard
qPCR Vector DNA Direct quantification of shed vector particles in excreta and fluids. GxP
ELISA Capsid Proteins / Antibodies Indirect measure of vector clearance and host immune response (NAb). GxP

MHRA-Compliant Study Design

Our scientific team designs vector shedding studies with UK and EU regulatory expectations as the primary framework. Protocols are structured to generate clear, interpretable data on the route, duration, and magnitude of vector shedding. This proactive alignment with MHRA guidance helps de-risk regulatory submissions and supports an efficient 18-24 month IND/CTA timeline. The quality and reliability of our vector analytics form the basis for long-term collaborations.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
– Biotech Partner

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Insights from Vector Biology

The principles of vector design directly influence biodistribution and shedding outcomes. Research into pseudotyped AAV vectors has demonstrated how capsid selection (e.g., AAV2/8) is a determinant of transduction efficiency and persistence in specific target tissues, such as airway epithelium (PMID: 22937069). Understanding this tropism is foundational to designing logical and informative shedding studies.

The vector payload can influence the biological environment. Studies using AAV vectors to deliver immune-modulating genes show the platform’s capacity to reconstitute functional immune cell populations (PMID: 24516613). This highlights the importance of integrating vector shedding data with immunogenicity assessments to build a complete safety profile.

GxP-Ready Bioanalytical Laboratories

All GxP bioanalysis is conducted within our >100,000 square foot facility, which houses dedicated laboratory space for molecular biology, immunoassays, and cell-based assays.

])

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities